These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 11275255

  • 1. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.
    Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R.
    Mol Immunol; 2000; 37(12-13):697-706. PubMed ID: 11275255
    [Abstract] [Full Text] [Related]

  • 2. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.
    Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P.
    J Mol Biol; 2003 Jan 31; 325(5):979-89. PubMed ID: 12527303
    [Abstract] [Full Text] [Related]

  • 3. Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry.
    Ghirlando R, Lund J, Goodall M, Jefferis R.
    Immunol Lett; 1999 May 03; 68(1):47-52. PubMed ID: 10397155
    [Abstract] [Full Text] [Related]

  • 4. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy.
    Yamaguchi Y, Nishimura M, Nagano M, Yagi H, Sasakawa H, Uchida K, Shitara K, Kato K.
    Biochim Biophys Acta; 2006 Apr 03; 1760(4):693-700. PubMed ID: 16343775
    [Abstract] [Full Text] [Related]

  • 5. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T, Thomann M, Rueger P, Knaupp A, Buchner J, Schlothauer T.
    PLoS One; 2015 Apr 03; 10(12):e0143520. PubMed ID: 26657484
    [Abstract] [Full Text] [Related]

  • 6. Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I.
    Lund J, Takahashi N, Popplewell A, Goodall M, Pound JD, Tyler R, King DJ, Jefferis R.
    Eur J Biochem; 2000 Dec 03; 267(24):7246-57. PubMed ID: 11106438
    [Abstract] [Full Text] [Related]

  • 7. Isotype and glycoform selection for antibody therapeutics.
    Jefferis R.
    Arch Biochem Biophys; 2012 Oct 15; 526(2):159-66. PubMed ID: 22465822
    [Abstract] [Full Text] [Related]

  • 8. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
    Wada R, Matsui M, Kawasaki N.
    MAbs; 2019 Oct 15; 11(2):350-372. PubMed ID: 30466347
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M.
    Glycobiology; 2007 Jan 15; 17(1):104-18. PubMed ID: 17012310
    [Abstract] [Full Text] [Related]

  • 11. Glycobiology: 'the function of sugar in the IgG molecule'.
    Dwek RA, Lellouch AC, Wormald MR.
    J Anat; 1995 Oct 15; 187 ( Pt 2)(Pt 2):279-92. PubMed ID: 7591992
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors.
    Radaev S, Sun PD.
    J Biol Chem; 2001 May 11; 276(19):16478-83. PubMed ID: 11297533
    [Abstract] [Full Text] [Related]

  • 14. CD16a with oligomannose-type N-glycans is the only "low-affinity" Fc γ receptor that binds the IgG crystallizable fragment with high affinity in vitro.
    Subedi GP, Barb AW.
    J Biol Chem; 2018 Oct 26; 293(43):16842-16850. PubMed ID: 30213862
    [Abstract] [Full Text] [Related]

  • 15. Functional diversification of IgGs through Fc glycosylation.
    Wang TT, Ravetch JV.
    J Clin Invest; 2019 Sep 03; 129(9):3492-3498. PubMed ID: 31478910
    [Abstract] [Full Text] [Related]

  • 16. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation.
    Ha S, Ou Y, Vlasak J, Li Y, Wang S, Vo K, Du Y, Mach A, Fang Y, Zhang N.
    Glycobiology; 2011 Aug 03; 21(8):1087-96. PubMed ID: 21470983
    [Abstract] [Full Text] [Related]

  • 17. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation.
    Jefferis R, Lund J, Pound JD.
    Immunol Rev; 1998 Jun 03; 163():59-76. PubMed ID: 9700502
    [Abstract] [Full Text] [Related]

  • 18. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
    Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E.
    Protein Eng Des Sel; 2016 Oct 03; 29(10):457-466. PubMed ID: 27578889
    [Abstract] [Full Text] [Related]

  • 19. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding.
    Mimura Y, Sondermann P, Ghirlando R, Lund J, Young SP, Goodall M, Jefferis R.
    J Biol Chem; 2001 Dec 07; 276(49):45539-47. PubMed ID: 11567028
    [Abstract] [Full Text] [Related]

  • 20. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides.
    Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG, Dwek RA.
    Biochemistry; 1997 Feb 11; 36(6):1370-80. PubMed ID: 9063885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.